blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2753337

EP2753337 - COMPOSITIONS INCLUDING BETA-GLUCANS AND METHODS OF USE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  28.06.2019
Database last updated on 19.07.2024
FormerThe patent has been granted
Status updated on  20.07.2018
FormerGrant of patent is intended
Status updated on  22.03.2018
FormerExamination is in progress
Status updated on  03.03.2018
FormerGrant of patent is intended
Status updated on  23.10.2017
FormerExamination is in progress
Status updated on  16.12.2016
Most recent event   Tooltip03.07.2020Lapse of the patent in a contracting state
New state(s): CY, MK		published on 05.08.2020  [2020/32]
Applicant(s)For all designated states
Biothera, Inc.
3388 Mike Collins Drive
Eagan, MN 55121 / US
[2014/29]
Inventor(s)01 / GORDEN, Keith B.
9345 Lake Road
Woodbury Minnesota 55125 / US
02 / BOSE, Nandita
4390 Merrimac Lane
Plymouth Minnesota 55446 / US
03 / CHAN, Anissa S.H.
4354 Arden View Court
Arden Hills Minnesota 55112 / US
04 / GROSSMAN, William J.
208 Mainsail Drive
Third Lake Illinois 60030 / US
 [2014/29]
Representative(s)Potter Clarkson
Chapel Quarter
Mount Street
Nottingham NG1 6HQ / GB
[N/P]
Former [2018/34]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham NG1 5GG / GB
Former [2014/29]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham, NG1 5GG / GB
Application number, filing date12829310.707.09.2012
[2018/34]
WO2012US54071
Priority number, dateUS201161532647P09.09.2011         Original published format: US 201161532647 P
[2014/29]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013036712
Date:14.03.2013
Language:EN
[2013/11]
Type: A1 Application with search report 
No.:EP2753337
Date:16.07.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 14.03.2013 takes the place of the publication of the European patent application.
[2014/29]
Type: B1 Patent specification 
No.:EP2753337
Date:22.08.2018
Language:EN
[2018/34]
Search report(s)International search report - published on:US14.03.2013
(Supplementary) European search report - dispatched on:EP28.01.2015
ClassificationIPC:A61K31/716, A61K39/39, A61K39/00, // A61P37/04
[2017/45]
CPC:
A61K39/39 (EP,US); A61K31/4738 (EP,US); A61K31/7084 (EP,US);
A61K31/716 (EP,US); A61P35/00 (EP); A61P37/04 (EP);
A61K2039/55511 (EP,US); A61K2039/55561 (EP,US); A61K2039/55572 (EP,US);
A61K2039/55583 (EP,US) (-)
C-Set:
A61K31/4738, A61K2300/00 (EP,US);
A61K31/7084, A61K2300/00 (US,EP);
A61K31/716, A61K2300/00 (US,EP)
Former IPC [2014/29]A61K31/716, A61K39/39
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/29]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ZUSAMMENSETZUNGEN MIT BETA-GLUCANEN UND VERWENDUNGSVERFAHREN[2014/29]
English:COMPOSITIONS INCLUDING BETA-GLUCANS AND METHODS OF USE[2014/29]
French:COMPOSITIONS COMPRENANT DES BÊTA-GLUCANES ET LEURS PROCÉDÉS D'UTILISATION[2014/29]
Entry into regional phase08.04.2014National basic fee paid 
08.04.2014Search fee paid 
08.04.2014Designation fee(s) paid 
08.04.2014Examination fee paid 
Examination procedure08.04.2014Examination requested  [2014/29]
12.08.2015Amendment by applicant (claims and/or description)
19.08.2016Despatch of a communication from the examining division (Time limit: M06)
24.02.2017Reply to a communication from the examining division
24.10.2017Communication of intention to grant the patent
23.02.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
23.03.2018Communication of intention to grant the patent
11.07.2018Fee for grant paid
11.07.2018Fee for publishing/printing paid
11.07.2018Receipt of the translation of the claim(s)
Divisional application(s)EP18162621.9  / EP3354319
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  19.08.2016
Opposition(s)23.05.2019No opposition filed within time limit [2019/31]
Fees paidRenewal fee
29.09.2014Renewal fee patent year 03
28.09.2015Renewal fee patent year 04
27.09.2016Renewal fee patent year 05
27.09.2017Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU07.09.2012
AL22.08.2018
AT22.08.2018
CY22.08.2018
CZ22.08.2018
DK22.08.2018
EE22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
MC22.08.2018
MK22.08.2018
NL22.08.2018
PL22.08.2018
PT22.08.2018
RO22.08.2018
RS22.08.2018
SE22.08.2018
SI22.08.2018
SK22.08.2018
SM22.08.2018
TR22.08.2018
LU07.09.2018
MT07.09.2018
BE30.09.2018
CH30.09.2018
LI30.09.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
[2020/31]
Former [2020/28]HU07.09.2012
AL22.08.2018
AT22.08.2018
CZ22.08.2018
DK22.08.2018
EE22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
MC22.08.2018
NL22.08.2018
PL22.08.2018
PT22.08.2018
RO22.08.2018
RS22.08.2018
SE22.08.2018
SI22.08.2018
SK22.08.2018
SM22.08.2018
TR22.08.2018
LU07.09.2018
MT07.09.2018
BE30.09.2018
CH30.09.2018
LI30.09.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2020/17]AL22.08.2018
AT22.08.2018
CZ22.08.2018
DK22.08.2018
EE22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
MC22.08.2018
NL22.08.2018
PL22.08.2018
RO22.08.2018
RS22.08.2018
SE22.08.2018
SI22.08.2018
SK22.08.2018
SM22.08.2018
TR22.08.2018
LU07.09.2018
MT07.09.2018
BE30.09.2018
CH30.09.2018
LI30.09.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2020/08]AL22.08.2018
AT22.08.2018
CZ22.08.2018
DK22.08.2018
EE22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
MC22.08.2018
NL22.08.2018
PL22.08.2018
RO22.08.2018
RS22.08.2018
SE22.08.2018
SI22.08.2018
SK22.08.2018
SM22.08.2018
LU07.09.2018
MT07.09.2018
BE30.09.2018
CH30.09.2018
LI30.09.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2019/40]AL22.08.2018
AT22.08.2018
CZ22.08.2018
DK22.08.2018
EE22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
MC22.08.2018
NL22.08.2018
PL22.08.2018
RO22.08.2018
RS22.08.2018
SE22.08.2018
SI22.08.2018
SK22.08.2018
SM22.08.2018
LU07.09.2018
BE30.09.2018
CH30.09.2018
LI30.09.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2019/38]AL22.08.2018
AT22.08.2018
CZ22.08.2018
DK22.08.2018
EE22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
MC22.08.2018
NL22.08.2018
PL22.08.2018
RO22.08.2018
RS22.08.2018
SE22.08.2018
SI22.08.2018
SK22.08.2018
SM22.08.2018
LU07.09.2018
BE30.09.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2019/37]AL22.08.2018
AT22.08.2018
CZ22.08.2018
DK22.08.2018
EE22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
MC22.08.2018
NL22.08.2018
PL22.08.2018
RO22.08.2018
RS22.08.2018
SE22.08.2018
SI22.08.2018
SK22.08.2018
SM22.08.2018
LU07.09.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2019/30]AL22.08.2018
AT22.08.2018
CZ22.08.2018
DK22.08.2018
EE22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
MC22.08.2018
NL22.08.2018
PL22.08.2018
RO22.08.2018
RS22.08.2018
SE22.08.2018
SK22.08.2018
SM22.08.2018
LU07.09.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2019/28]AL22.08.2018
AT22.08.2018
CZ22.08.2018
DK22.08.2018
EE22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
MC22.08.2018
NL22.08.2018
PL22.08.2018
RO22.08.2018
RS22.08.2018
SE22.08.2018
SK22.08.2018
SM22.08.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2019/26]AL22.08.2018
AT22.08.2018
CZ22.08.2018
DK22.08.2018
EE22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
NL22.08.2018
PL22.08.2018
RO22.08.2018
RS22.08.2018
SE22.08.2018
SK22.08.2018
SM22.08.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2019/23]AL22.08.2018
AT22.08.2018
CZ22.08.2018
EE22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
NL22.08.2018
PL22.08.2018
RO22.08.2018
RS22.08.2018
SE22.08.2018
SK22.08.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2019/22]AL22.08.2018
CZ22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
NL22.08.2018
PL22.08.2018
RO22.08.2018
RS22.08.2018
SE22.08.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2019/12]AL22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
NL22.08.2018
RS22.08.2018
SE22.08.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2019/11]FI22.08.2018
HR22.08.2018
LT22.08.2018
NL22.08.2018
RS22.08.2018
SE22.08.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2019/10]FI22.08.2018
LT22.08.2018
NL22.08.2018
RS22.08.2018
SE22.08.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2019/09]FI22.08.2018
LT22.08.2018
NL22.08.2018
NO22.11.2018
IS22.12.2018
Former [2019/08]FI22.08.2018
LT22.08.2018
NO22.11.2018
IS22.12.2018
Former [2019/07]LT22.08.2018
Documents cited:Search[XY]  - HAIBIN HUANG ET AL, "Distinct Patterns of Dendritic Cell Cytokine Release Stimulated by Fungal -Glucans and Toll-Like Receptor Agonists", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 77, no. 5, doi:10.1128/IAI.00086-09, ISSN 0019-9567, (20090501), pages 1774 - 1781, (20090309), XP007915686 [X] 1 * abstract; last full § of p. 1776; Fig. 4; p. 1776, last full sentence of col. 1 * [Y] 1-15

DOI:   http://dx.doi.org/10.1128/IAI.00086-09
 [XY]  - SELVARAJ V ET AL, "Adjuvant and immunostimulatory effects of beta-glucan administration in combination with lipopolysaccharide enhances survival and some immune parameters in carp challenged with Aeromonas hydrophila", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, ELSEVIER BV, AMSTERDAM, NL, vol. 114, no. 1-2, doi:10.1016/J.VETIMM.2006.06.011, ISSN 0165-2427, (20061115), pages 15 - 24, (20061115), XP024998912 [X] 1,3,4,8-12 * abstract; Fig. 2; * [Y] 1-15

DOI:   http://dx.doi.org/10.1016/j.vetimm.2006.06.011
 [Y]  - JUN LI ET AL, "Effects of [beta]-glucan extracted from Saccharomyces cerevisiae on humoral and cellular immunity in weaned piglets", ARCHIVES OF ANIMAL NUTRITION, (20051001), vol. 59, no. 5, doi:10.1080/17450390500247832, ISSN 1745-039X, pages 303 - 312, XP055163111 [Y] 1-15 * abstract; p. 307: section 3.1 *

DOI:   http://dx.doi.org/10.1080/17450390500247832
 [Y]  - H. T. L. LAI ET AL, "Effects of dust and airborne dust components on antibody responses, body weight gain, and heart morphology of broilers", POULTRY SCIENCE, (20090817), vol. 88, no. 9, doi:10.3382/ps.2009-00129, ISSN 0032-5791, pages 1838 - 1849, XP055163217 [Y] 1-15 * table I; see 1840, col. 1, l. 12 of second § *

DOI:   http://dx.doi.org/10.3382/ps.2009-00129
 [Y]  - TOKUNAKA K ET AL, "Immunopharmacological and immunotoxicological activities of a water-soluble (1->3)-beta-D-glucan, CSBG from Candida spp", INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, ELMSFORD,NY, US, (20000501), vol. 22, no. 5, doi:10.1016/S0192-0561(99)00093-4, ISSN 0192-0561, pages 383 - 394, XP002264610 [Y] 1-15 * Fig. 3; p. 387, section 3.2 *

DOI:   http://dx.doi.org/10.1016/S0192-0561(99)00093-4
International search[Y]US6143883  (LEHMANN JOACHIM [US], et al);
 [Y]US2004127458  (HUNTER KENNETH W [US], et al);
 [Y]US2008160089  (VITIELLO MARIA A [US], et al);
 [Y]US2008167268  (YAN JUN [US]);
 [Y]  - HARNACK ET AL., "Oral administration of a soluble 1-3, 1-6 beta-glucan during prophylactic survivin peptide vaccination diminishes growth of a B cell lymphoma in mice", INTERNATIONAL IMMUNOPHARMACOLOGY, (2009), vol. 9, pages 1298 - 1303, XP026614224

DOI:   http://dx.doi.org/10.1016/j.intimp.2009.07.013
ExaminationWO2006119395
    - ANA-LUCIA FUENTES ET AL, "Laminarin, a soluble beta-glucan, inhibits macrophage phagocytosis of zymosan but has no effect on lipopolysaccharide mediated augmentation of phagocytosis", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 11, no. 11, doi:10.1016/J.INTIMP.2011.08.005, ISSN 1567-5769, (20110803), pages 1939 - 1945, (20110811), XP028326780

DOI:   http://dx.doi.org/10.1016/j.intimp.2011.08.005
    - Charlotte Sissener Engstad ET AL, "The effect of soluble [beta]-1,3-glucan and lipopolysaccharide on cytokine production and coagulation activation in whole blood", INTERNATIONAL IMMUNOPHARMACOLOGY, NL, (20021001), vol. 2, no. 11, doi:10.1016/S1567-5769(02)00134-0, ISSN 1567-5769, pages 1585 - 1597, XP055295070

DOI:   http://dx.doi.org/10.1016/S1567-5769(02)00134-0
    - FRASNELLI MATTHIAS E ET AL, "TLR2 modulates inflammation in zymosan-induced arthritis in mice", ARTHRITIS RESEARCH, CURRENT SCIENCE, LONDON, GB, (20050121), vol. 7, no. 2, doi:10.1186/AR1494, ISSN 1465-9905, pages R370 - R379, XP021011575

DOI:   http://dx.doi.org/10.1186/ar1494
    - Shunsuke Hida ET AL, "Cell Wall [beta]-Glucan Derived from Candida albicans Acts as a Trigger for Autoimmune Arthritis in SKG Mice", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN), JP, (20070101), vol. 30, no. 8, doi:10.1248/bpb.30.1589, ISSN 0918-6158, pages 1589 - 1592, XP055295192

DOI:   http://dx.doi.org/10.1248/bpb.30.1589
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.